Savaraj N, Feun L G, Lu K, Leavens M, Moser R, Fields W S, Loo T L
J Neurooncol. 1987;5(1):77-81. doi: 10.1007/BF00162769.
Generally tritiated homoharringtonine ([3H]HHT, 150 microCi, 430 micrograms) was administered intravenously to seven patients at varying times before surgical resection of malignant brain tumor. Plasma, urine, cerebrospinal fluid (CSF), and tumor specimens were obtained during surgery, and the concentrations of HHT, its major metabolite, and [3H]HHT equivalent were determined chromatographically and radiochemically. For [3H]HHT equivalent, the concentration in tumor ranged from 0.6 to 4.3 ng/g and the ratio of tumor to plasma concentration from 0.5 to 1.8. In one patient who had CSF available for drug determination, the CSF to plasma ratio of total [3H]HHT was 0.3 at 45 minutes after drug administration and less than 0.2 ng/ml was unchanged HHT. For unchanged HHT, drug concentration in tumor ranged from undetectable (4 patients) to 1.8 ng/g. A major metabolite of HHT was detectable in the tumor specimens of all the patients. These results indicate that homoharringtonine can penetrate into brain tumors; in 3 patients with brain tumors, the ratios of HHT concentration in the tumor to that in the concurrent plasma were greater than one.
一般来说,在对7例恶性脑肿瘤患者进行手术切除前的不同时间,静脉注射氚标记高三尖杉酯碱([3H]HHT,150微居里,430微克)。在手术期间采集血浆、尿液、脑脊液(CSF)和肿瘤标本,并通过色谱法和放射化学法测定HHT、其主要代谢物以及[3H]HHT等效物的浓度。对于[3H]HHT等效物,肿瘤中的浓度范围为0.6至4.3纳克/克,肿瘤与血浆浓度之比为0.5至1.8。在1例可获得用于药物测定的脑脊液的患者中,给药后45分钟时,总[3H]HHT的脑脊液与血浆之比为0.3,未变化的HHT低于0.2纳克/毫升。对于未变化的HHT,肿瘤中的药物浓度范围为不可检测(4例患者)至1.8纳克/克。在所有患者的肿瘤标本中均检测到HHT的一种主要代谢物。这些结果表明高三尖杉酯碱能够渗透到脑肿瘤中;在3例脑肿瘤患者中,肿瘤中HHT浓度与同期血浆中HHT浓度之比大于1。